The KNOP1 Knockout HeLa Polyclonal Cells product is a CRISPR/Cas9-edited heterogeneous population of HeLa cells with targeted disruption of the KNOP1 gene, providing a loss-of-function model for investigating the PRP19 complex in human cells. This polyclonal knockout pool is generated through transient expression of gene-specific guide RNAs and Cas9 nuclease, followed by selection for edited cells, without clonal isolation. As a ready-to-use format, the population retains genetic diversity while offering robust target-gene ablation, enabling immediate deployment in functional studies. The polyclonal nature minimizes clonal artifacts and is especially suited for assays requiring population-level readouts. Researchers can bypass the labor-intensive steps of single-cell cloning and clone verification, accelerating experimental timelines in spliceosome biology.
The host cell line, HeLa, is an immortalized adherent epithelial cell line originally derived from a cervical adenocarcinoma of a patient harboring HPV18. HeLa cells are among the most widely employed models in biomedical research due to their rapid proliferation, extensive molecular characterization, and adaptability to diverse experimental techniques. The cervical carcinoma origin renders these cells particularly pertinent for studying oncogenic pathways and viral-host interactions, including splicing dysregulation in HPV-transformed contexts. Their well-documented transcriptome and epigenome make HeLa cells an ideal chassis for investigating fundamental mechanisms of gene expression, cell cycle control, and apoptosis.
KNOP1 encodes a core subunit of the PRP19 complex (nineteen complex, NTC), a spliceosomal subcomplex essential for pre-mRNA splicing catalysis. Mechanistically, KNOP1 is recruited to assembling spliceosomes and facilitates the structural transition from the pre-catalytic B complex to the activated Bact complex, thereby promoting stable integration of the U4/U6.U5 tri-snRNP. The protein interacts directly with PRPF19, CDC5L, PLRG1, BCAS2, and SPF27 within the NTC, and it functionally cooperates with core spliceosome components such as SNRNP200 and PRPF8. Downstream, KNOP1 influences the splicing of numerous pre-mRNA substrates, including alternative splicing targets that shape proteome diversity. Disruption of KNOP1 perturbs spliceosome activation kinetics, leading to global changes in splicing patterns that can impact cell survival and proliferation.
In the HeLa cellular context, KNOP1 knockout provides a potent system to explore the dependency of cancer cells on proper spliceosome function. Cervical carcinoma cells often exhibit aberrant splicing programs, and the loss of a key splicing cofactor like KNOP1 can expose vulnerabilities in RNA processing networks. This model enables dissection of how impaired PRP19 complex activity affects cell fitness, apoptosis, and transcriptomic output in an HPV-positive background. Moreover, it serves as a relevant platform for testing the efficacy of splicing-modulating compounds in a cancer-derived epithelial setting, bridging basic splicing research and therapeutic development.
This KNOP1 knockout population is suited for a broad array of applications, including RNA-seq to profile global splicing alterations, RT-qPCR for quantifying specific splice variants, co-immunoprecipitation to assess protein?Cprotein interactions within the spliceosome, and functional assays such as cell proliferation and apoptosis measurements. The polyclonal format is particularly advantageous for high-throughput drug screening against splicing inhibitors, as it reduces clonal bias while maintaining target-gene disruption. Western blotting and immunofluorescence can confirm KNOP1 depletion and subcellular localization defects. For detailed product information and technical support, please contact Ascent Research.
